Clinical Trial Update: Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on using allogeneic blood lymphocytes activated with recombinant interleukin-2 (rIL-2) to treat metastatic solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Allogeneic blood lymphocytes activated with recombinant interleukin-2 (rIL-2)

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Tumors | Phase 2 | Status: UNKNOWN